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Nowadays, increasing extended‑spectrum β‑lactamase (ESBL)‑producing bacteria have become a 
global concern because of inducing resistance toward most of the antimicrobial classes and making 
the treatment difficult. In order to achieve an appropriate treatment option, identification of the 
prevalent species which generate ESBL as well as their antibiotic susceptibility pattern is essential 
worldwide. Hence, this study aimed to investigate the prevalence of ESBL‑producing bacteria 
and assess their drug susceptibility in Fardis Town, Iran. A total of 21,604 urine samples collected 
from patients suspected to have urinary tract infection (UTI) were processed in the current study. 
The antimicrobial susceptibility of the isolates was tested by the disk diffusion method. The ESBL 
producing bacteria were determined by Double Disc Synergy Test (DDST) procedure. Bacterial growth 
was detected in 1408 (6.52%) cases. The most common bacterial strains causing UTI were found E. 
coli (72.16%), followed by K. pneumoniae (10.3%) and S. agalactiae (5.7%). Overall, 398 (28.26%) 
were ESBL producer. The highest ESBL production was observed in E. coli, followed by Klebsiella 
species. ESBL producers revealed a higher level of antibiotic resistance compared with non‑ESBLs. In 
conclusion, ESBL production in uropathogens was relatively high. Carbapenems and Aminoglycosides 
were confirmed as the most effective treatment options for these bacteria.
For decades, antibiotics have been used for the treatment of bacterial infections successfully; however, over the 
past few years, the abuse of antibiotics has led to the emergence of antimicrobial resistance around the world 
and has become a serious global threat to the public  health1,2. Recently, it has been reported that approximately 
700,000 people worldwide die annually from antimicrobial resistance (AMR) infections and it has been predicted 
that this number would reach 10 million by  20503.
At present, β-lactam drugs are a key factor in the treatment of bacterial infections worldwide and account for 
almost 65% of antibiotic  usage4. They have been classified into six main groups based on the chemical structure of 
the β-lactam ring which includes Penicillins, Cephalosporins, Cephamycins, Carbapenems, Monobactams, and 
β-lactamase inhibitors. These drugs block cell wall synthesis by preventing accurate working of the Penicillin-
binding protein (PBP), which has a principal role in the synthesis of the bacterial cell wall, and finally leads to 
cellular death. Nevertheless, it is unfortunate that, in recent years, resistance to this important class of antibiotics 
is also increasing  globally5.
Resistance to b-lactams can occur through different mechanisms such as the generation of efflux pumps, 
changes in the production of outer membrane porins, alterations of PBPs, and the production of β-lactamase for 
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inactivating antibiotics. Of these mechanisms, the production of B-lactamases is the most prevalent source of 
resistance to β-lactam antibiotics which are produced by both Gram-positive (extracellularly) and Gram-negative 
(in the Periplasmic space) bacteria. These enzymes are able to make the β-lactam antibiotics inactive by bind-
ing covalently to their carbonyl section and hydrolyzing the b-lactam ring thus enabling β-lactam  resistance6,7.
To date, various β-lactamases have been reported to be generated by diverse microorganisms, including Peni-
cillinases, Extended-spectrum β-lactamases (ESBLs), Cephalosporinases (AmpC), Metallo-β-lactamases (MBLs), 
and Carbapenemases (KPCs). Among these, ESBL-producing bacteria are very important and have attracted 
the attention of the scientific  community8. ESBLs are β-lactamases enzymes with the capability to hydrolyze 
β-lactam antibiotics containing Penicillins, Aztreonam, as well as the first-, second-, third- and fourth-generation 
Cephalosporins, while sparing Cephamycins, Moxalactam, and Carbapenems. Further, they are inhibited by 
β-lactamase inhibitors, such as clavulanic acid, Tazobactam, and  Sulbactam8–10. ESBLs producing organisms 
may also induce resistance to some of the none β-lactam antibiotics including Aminoglycosides, Quinolones, 
and Trimethoprimsulfamath-oxazoles11.
Today, the outbreak of infections caused by ESBL producing pathogens is becoming increasingly frequent and 
has become a world health  threat12. The plasmid location of ESBL genes contributes to their spread through the 
horizontal gene transfer among the same and different species of  bacteria13. The prevalence of ESBL-producing 
isolates depends on some factors including species, geographic region, hospital/ward, group of patients and type 
of infection, and extensive overuse of  antibiotics14,15.
ESBLs are mostly produced by Gram-negative bacilli, especially Enterobacteriaceae  family8. ESBL-producing 
Enterobacteriaceae cause a variety of hospital and community-acquired infections such as bloodstream, wound 
infections, respiratory tract, and urinary tract  infections16. Urinary tract infections (UTIs) are very common 
infectious diseases that occur in a high proportion of the population and are a serious concern in the healthcare 
 system17. At present, Carbapenems are selective drugs for the effective treatment of infections caused by ESBL-
producing organisms. However, increasing Carbapenem resistance bacteria has also been associated with the 
use of  Carbapenems18,19.
Due to expanding antibiotic resistance among bacteria and the high distribution of ESBL producing isolates, 
the recognition of the prevalent species that produce this enzyme as well as their antibiotic susceptibility pat-
tern is necessary for each community to select the most effective treatment options. Thus, the aim of this study 
was to determine the prevalence of ESBL-producing bacteria and their antibiotic susceptibility pattern among 
uropathogens isolated from patients referring to the central laboratory of Fardis Town in Alborz province, Iran.
Materials and methods
Study population and samples processing. In the current descriptive cross-sectional study, 21,604 
urine samples were aseptically collected from patients suspected to have UTI who were referred to Fardis Town 
laboratory located in Alborz province, Iran during one year (2018–2019). Positive bacterial growth was detected 
in urine samples of 1408 (6.52%) patients. The specimens were cultivated on Blood Agar and Eosin Methyl-
ene Blue Agar (EMB) medium (Merck, Germany) and incubated at 37 °C for 24 h. Initially, the colonies were 
counted. In cultures with bacterial counts of > 104 cfu/ml, the specimens were considered as positive, and gram-
staining technique was performed. Then, bacterial genus and species were determined by standard biochemical 
tests.
Antimicrobial susceptibility testing. Antimicrobial susceptibility of the isolates was performed by the 
standard Kirby–Bauer disk diffusion method on the Mueller–Hinton agar media (Merck, Germany) using com-
mercially available antibiotic disks (Mast, UK). The diameter of inhibition zone was measured for each antibiotic 
disk, and the results were defined in accordance with the CLSI  guidelines20.
Phenotypic identification of ESBL‑producing strains. Detection of ESBL-producing organisms was 
performed by Double Disc Synergy Test (DDST) method following CLSI recommendations. In this method, 
first, a suspension was prepared for each pure bacterial isolate according to the 0.5 McFarland turbidity standard 
and cultured on Mueller–Hinton agar. Fifteen minutes after bacterial cultures, pairs of antibiotic disks contain-
ing Ceftazidime (30 μg) with Ceftazidime/Clavulanic acid (30/10 μg), and Cefotaxime (30 μg) with Cefotaxime/
Clavulanic acid (30/10 μg) were placed on Mueller–Hinton agar medium center to center, at a distance of 20 mm 
apart from each other. The plates were incubated for 24 h at 37 °C. Then, the diameter of inhibition zone was 
measured. According to CLSI guidelines, an increase of ≥ 5 mm in the zone diameter around the clavulanic acid 
combination disks versus the same disks alone confirmed the presence of ESBL producer  strains20.
Ethical considerations. All ethical aspects of this research have been completely observed by the authors. 
It was approved by Research and Ethics committee of the Iran University of Medical Sciences. All experiments 
were performed in accordance with relevant guidelines and regulations in Iran. Informed consent was obtained 
from all participants or their legal guardians before the study. The patient’s demographic characteristics were 
recorded in a questionnaire and their information remained confidential.
Data analysis. Data were analyzed using descriptive statistics (frequency and frequency percent, average 
and standard deviation), Chi square statistical test, and Fisher’s exact test, hierarchical clustering analysis on 
SPSS software version 22. The confidence limits for statistical tests were considered as 0.95.
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Results
Demographic information of the participants. Of a total of 21,604 participants surveyed in the present 
study, 15,408 (71.3%) were female and 6196 (28.7%) were male. The mean age of subjects was 23.21 ± 33.82 years 
and their age range was 3 months to 98 years (Table 1).
The results of urine culture. Positive bacterial growth was detected in urine samples of 1408 (6.52%) 
patients. Among uropathogens, E. coli (1016 cases, 72.16%) was the most commonly isolated species, followed 
by K. pneumoniae (144 cases, 10.3%) and S. agalactiae (80 cases, 5.7%). In addition, fungal infection was found 
in 223 cases. Out of the 1408 positive bacterial cultures, 1255 (89.13%) cases were related to females. As indi-
cated in Table 1, the patients mostly belonged to the age groups of 60–75 years old (283 cases, 20.11%) and 
45–60 years old (254 cases, 18%). In both genders, the main infectious strain was E. coli, while the proportion of 
E. faecalis infection in males was far higher than in females (13.07–2.47%) (Table 1).
Minority bacteria. Out of the 1408 culture positive cases, the minimum numbers of isolates were related to, 
Proteus mirabilis (11 cases, 1.6%), Proteus vulgaris (7 cases, 0.5%), Citrobacter freundii (5 cases, 0.35%), Entero-
bacter aerogenes (4 cases, 0.28%), Enterobacter agglomerans (3 cases, 0.2%), Non-Enterococcus bovis (2 cases, 
0.14%), Cn Staphylococci (11 cases, 1.6%), Staphylococcus aureus (9 cases, 0.64%), Staphylococcus saprophyticus 
strains (7 cases, 0.5%) (Table 1). There isn’t any strain producing ESBL among these bacteria.
Antimicrobial susceptibility profile and ESBL production. E. coli. Table  2 indicates the overall 
antimicrobial susceptibility pattern of E. coli for antibiotics tested. It shows that the highest sensitivity was ob-
served with Imipenem (99.2%), Amikacin (97.9%), Meropenem (97.2%), and Nitrofurantoin (92.8%), respec-
tively. Further, the least sensitivity was to Piperacillin (17%) and Ampicillin (19.1%). Out of 1016 E. coli isolated, 
359 (35.7%) were found to be ESBL producer. With the exception of Amikacin, Imipenem, Meropenem, and 
Nitrofurantoin, ESBL expression had a significant effect on E. coli resistance to other antibiotics tested (Table 2).
K. pneumoniae. According to Table 3, K. pneumoniae showed the highest rate of sensitivity towards Imipenem 
(99.3%), followed by Amikacin (95.8%), Meropenem (90%), and Gentamycin (90%), and the least sensitivity to 
tetracycline (0%), Tobramycin (0%), and Ampicillin (19.1%). From 144 K. pneumoniae isolates, 33 (22.9%) were 
Table 1.  Test result age group.
Result
Sex Age group
TotalMale Female Age ≤ 1 2–5 6–15 16–30 31–45 46–60 61–75 75 < Age
No bacteria growth 6012 13,837 1659 2047 1834 3257 4923 3228 2299 602 19,849
< 10,000 26 98 58 12 2 19 15 10 3 5 124
Candida albicans and non-albicans 5 218 1 0 5 73 89 23 18 14 223
Positive culture
Enterobacteriaceae
 Escherichia coli 94 922 125 56 83 101 161 196 204 90 1016
 Klebsiella pneumoniae 15 129 25 3 2 23 32 26 21 12 144
 Citrobacter diversus 2 21 7 0 0 0 1 3 6 6 23
 Klebsiella oxytoca 3 10 2 1 0 3 0 1 3 3 13
 Proteus mirabilis 2 9 6 1 1 1 1 0 1 0 11
 Proteus vulgaris 1 6 0 4 0 0 2 1 0 0 7
 Citrobacter freundii 3 2 0 1 0 1 0 0 3 0 5
 Enterobacter aerogenes 0 4 0 0 0 2 0 1 1 0 4
 Enterobacter agglomerans 0 3 0 0 0 1 0 0 1 1 3
Streptococcaceae
 Streptococcus agalactiae 2 78 0 0 4 19 24 13 14 6 80
 Enterococcus faecalis 20 31 7 1 4 2 5 12 13 7 51
 Non-Enterococcus bovis 1 1 1 0 0 0 0 0 0 1 2
Staphylococcaceae
 Cn Staphylococci 4 7 1 0 0 2 3 1 3 1 11
 Staphylococcus aureus 1 8 0 0 1 6 1 0 1 0 9
 Staphylococcus saprophyticus 1 6 0 0 0 3 3 0 0 1 7
Pseudomonadaceae
 Pseudomonas aeruginosa 4 12 2 1 2 0 1 3 2 5 16
Other 0 6 0 0 1 1 2 0 0 2 6
Total 6196 15,408 1894 2127 1939 3514 5263 3518 2593 756 21,604
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Table 2.  Antibiogram result of E. coli. *No significant statistical test was performed on these antibiotics, due 
to cases fewer than 6.
Antibiotics
Antibiogram result Statistical significance
Non-ESBL E. coli ESBL E. coli
Total
Pearson chi square/
Fisher’s exact testSensitive Intermediate Resistant Sensitive Intermediate Resistant
Ciprofloxacin 346 3 99 96 3 165 712 P value = 0.00
Norfloxacin 146 1 41 27 0 72 287 P value = 0.00
Amikacin 635 1 7 352 2 11 1008 P value = 0.046
Ceftazidime 570 2 60 6 0 351 989 P value = 0.00
Cefotaxime 485 5 35 7 1 301 834 P value = 0.00
Ceftriaxone 88 0 22 2 0 53 165 P value = 0.00
Gentamycin 591 5 45 228 3 131 1003 P value = 0.00
Imipenem 582 0 4 332 0 3 921 P value = 0.720
Meropenem 47 0 1 29 0 1 78 P value = 0.734
Nitrofurantoin 610 15 24 330 12 22 1013 P value = 0.138
Cefalexin 480 16 151 5 1 359 1012 P value = 0.00
Ampicillin 191 3 449 2 0 364 1009 P value = 0.00
Nalidixic-acid 333 14 301 56 7 302 1013 P value = 0.00
Co-Trimoxazole 321 10 311 48 2 313 1005 P value = 0.00
Azithromycin 2 0 0 0 0 1 3
*
Colistin 2 0 1 1 0 0 4
Doxycycline 1 0 1 1 1 0 4
Chloramphenicol 2 0 0 1 0 2 5
Piperacillin 1 0 2 0 0 3 6
Tetracycline 1 0 1 0 0 1 3
Tobramycin 0 0 0 3 0 2 5
Table 3.  Antibiogram result of K. pneumoniae. *Due to fewer than 5 cases, no statistical test was conducted 
for these antibiotics.
Antibiotics
Antibiogram result Statistical significance
Non-ESBL K. pneumoniae ESBL K. pneumoniae
Total
Pearson chi square/
Fisher’s exact testSensitive Intermediate Resistant Sensitive Intermediate Resistant
Ciprofloxacin 73 0 9 15 0 8 105 P value = 0.011
Norfloxacin 24 1 4 5 0 5 39 P value = 0.060
Amikacin 109 0 2 28 0 4 143 P value = 0.023
Ceftazidime 100 0 8 1 0 32 141 P value = 0.00
Cefotaxime 73 0 6 0 0 26 105 P value = 0.00
Ceftriaxone 28 0 3 1 0 5 37 P value = 0.001
Gentamycin 104 0 3 22 1 10 140 P value = 0.00
Imipenem 103 0 0 30 0 1 134 P value = 0.231
Meropenem 8 0 0 1 0 1 10 P value = 0.200
Nitrofurantoin 50 39 22 17 6 10 144 P value = 0.148
Cefalexin 94 1 16 1 0 32 144 P value = 0.00
Ampicillin 5 0 105 0 0 32 142 P value = 0.273
Nalidixic-acid 88 2 21 13 1 19 144 P value = 0.00
Co-Trimoxazole 68 2 41 4 0 29 144 P value = 0.00
Colistin 1 0 0 1 0 1 3
*
Chloramphenicol 0 0 1 1 0 0 2
Piperacillin 1 0 0 1 0 1 3
Tetracycline 0 0 1 0 0 1 2
Tobramycin 0 0 0 0 0 2 2
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confirmed as ESBL producer. The expression of ESBL resulted in developing resistance to the antibiotics Ceftazi-
dime, Cefotaxime, Ceftriaxone, Gentamycin, Cefalexin, Nalidixic-acid, and Co-trimoxazole.
K. oxytoca. The information presented in Table 4 shows that all K. oxytoca isolates were reactive towards Imi-
penem with a sensitivity rate of 100% followed by Amikacin (92.3%). However, none of the isolates was sensi-
tive to Ampicillin (0%). Of the 23 positive urine cultures of K. oxytoca, 5 (38.46%) were confirmed as ESBL 
positive. ESBL-producing isolates were highly resistant to Ceftazidime, Cefotaxime, Norfloxacin, Cefalexin, and 
Co-trimoxazole.
S. agalactiae. The antibiotic susceptibility pattern of S. agalactiae revealed that the majority of the isolates were 
sensitive to Linezolid (98.7%), Ampicillin (97.5%), Cefalexin (97.4%), and Nitrofurantoin (96.2%), and the least 
susceptibility was to Co-trimoxazole (1.3%) (Fig. 1).
E. faecalis. According to the results of antibiogram for E. faecalis, Nitrofurantoin (98%), Linezolid (97.9%), and 
Ampicillin (96%) revealed a superior sensibility for this bacterium. On the other hand, low level of susceptibility 
was observed in Co-trimoxazole (2%) and Cefalexin (8.3%) (Fig. 2).
C. diversus. In the case of C. diversus, Ceftriaxone (100%), Amikacin (95.5%), and Imipenem (95.5%) were 
found to be most effective antibiotics. However, Ampicillin (8.7%) and Nalidixic-acid (59.1%) showed the least 
susceptibility rate (Fig. 3). Among 23 C. diversus isolates screened for ESBL, one of them was positive for ESBL 
production which was resistant to antibiotics tested, except of Amikacin and Imipenem.
Table 4.  Antibiogram result of K. oxytoca. *No statistical test was conducted for these antibiotics.
Antibiotics
Antibiogram result Statistical significance
Non-ESBL K. oxytoca ESBL K. oxytoca
Total
Pearson chi square/
Fisher’s exact testSensitive Intermediate Resistant Sensitive Intermediate Resistant
Norfloxacin 6 1 1 1 0 4 13 P value = 0.050
Amikacin 8 0 0 4 0 1 13 P value = 0.385
Ceftazidime 8 0 0 0 0 5 13 P value = 0.001
Cefotaxime 7 0 1 0 0 5 13 P value = 0.005
Gentamycin 8 0 0 3 0 2 13 P value = 0.128
Imipenem 8 0 5 0 0 13 *
Nitrofurantoin 6 1 1 2 3 0 13 P value = 0.174
Cefalexin 7 0 1 0 0 5 13 P value = 0.005
Ampicillin 0 0 8 0 0 5 13 *
Nalidixic-acid 6 0 2 4 1 0 13 P value = 0.025
Co-Trimoxazole 6 1 1 1 0 4 13 P value = 0.050













Figure 1.  Antibiogram result of S. agalactiae. 
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P. aeruginosa. As depicted in Fig. 4, the least sensitivity rate for P. aeruginosa isolates was against Cefalexin 
(7.1%) and Cefotaxime (15.4%).
Hierarchical clustering analysis. Using Hierarchical cluster analysis for pattern of antibiotic effect for 
ESBL-negative/positive bacterial strains, we plotted 11 commonly used antibiotics for three of the bacterial 
strains producing ESBL (E. coli, K. pneumoniae and K. oxytoca). The goal was to cluster antibiotics with simi-
lar efficacy. Clustering was done by the nearest neighbor method and Minkowski measure. Figures  5 and 6 
(Dendrogram plots) show the clustering of antibiotics with similar effects for ESBL-negative and ESBL-positive 
bacterial strains. 
As depicted in Fig. 5, the two antibiotics Amikacin and Imipenem were most similar in their effect on ESBL-
negative bacterial strains.
As depicted in Fig. 6, the antibiotics Ampicillin, Cephalexin, Ceftazidime, and Cefotaxime had the most 
similarity in their effect on ESBL-positive bacterial strains.
Discussion
Urinary tract infection (UTI) is the second common infectious disease throughout the world caused by a wide 
range of microbial  pathogens21. In the present work, from 21,604 suspected UTI patients, 1408 (6.52%) uropatho-






























Figure 3.  Antibiogram result of C. diversus. 
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majority of the isolates were obtained from females 1255 (89.13%). This finding is supported by other studies 
reporting a higher rate of UTI prevalence in female patients compared to  males14,22. These studies suggest that 
females are more at risk of developing infection by uropathogens which is due to their anatomical  structure23. 
In terms of age, it was found that the most frequently uropathogens were related to the age groups of 60–75 
(20.11%) and 45–60 (18%) years old. These outcomes agree with previous studies in which the incidence of UTIs 
was higher among elderly  patients24,25.
The members of Enterobacteriaceae family especially E. coli and Klebsiella spp. are identified as vital causa-
tive agents of UTIs as they possess a number of factors including adhesion, pilli, fimbrae, and P1 blood group 
genotype receptor, which contribute to the attachment of bacteria to the  urothelium26. In this regard, here the 
predominant urinary isolates were E. coli 1016 (72.16%) followed by K. pneumoniae 144 (10.3%). These results 
are in line with the earlier studies conducted by other  researchers27–29. In addition, we found S. agalactiae 80 
(5.7%) as the most frequently isolated Gram-positive bacterium involved in UTI.












Figure 4.  Antibiogram result of P. aeruginosa. 
Figure 5.  Clustering pattern of antibiotic effect for ESBL-negative bacterial strains.
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At present, increasing Enterobacteriaceae producing ESBLs is a global healthcare concern because of high 
antibiotic resistance and the restricted treatment  options30. In this survey, ESBL production was found in 28.26% 
(398/1408). In line with this result, some researchers reported the rate of ESBL production as 29% and 30.23%31,32. 
In contrast, an earlier study revealed that 11.75% of uropathogens were ESBL  positive33 which is lower than our 
result. Elsewhere, the researcher reported 55.4% for ESBL production rate which is larger than  ours34. These 
differences may be due to geographical area, time, and the diagnostic technique  used32.
Among the ESBL producers, the highest rate was observed in E. coli (35.7%), followed by Klebsiella spp. 
(22.7%) and C. diversus (4.34%). This is in accordance with other studies in which among various ESBL isolates, 
E. coli species was the most prominent isolates followed by Klebsiella spp. On the other hand, the minimum 
ESBL isolates were related to Citrobacter spp.35–37. In contrast, several studies reported the highest ESBL produc-
tion among K. pneumoniae followed by E. coli which do not match our  results38–40, since we found E. coli as the 
predominant ESBL producer.
The antibiotic susceptibility testing by commonly prescribed antibiotics was accomplished for the most fre-
quent pathogens found in our study. In determining the antibiotic susceptibility patterns of E. coli, a high level 
of sensitivity to Imipenem (99.2%), Amikacin (97.9%), Meropenem (97.2%), and Nitrofurantoin (92.8%) was 
observed, while the least sensitivity was related to Piperacillin (17%) and Ampicillin (19.1%). Most studies on 
the antibiotic susceptibility of urinary pathogens around the world have found similar results. For example, in 
Ahmed et al.’s study, E. coli showed high resistance to Ampicillin and Piperacillin, and low resistance rates against 
Meropenem, Amikacin, and  Nitrofurantoin41. In another study by Mohammed et al., isolated E. coli was highly 
sensitive to Amikacin, Imipenem, and Meropenem, and extremely resistant to  Ampicillin42. Shakibaie et al. 
exhibited that uropathogenic E. coli were 100% sensitive to Imipenem and Meropenem, and 94.4% to Amikacin, 
while all of them were resistant to  Ampicillin43. Another study conducted by Koshesh et al. revealed a low rate 
of resistance to Imipenem for E. coli  uropathogens44. In Khan et al.’s study, E. coli showed 96.2% susceptibility to 
Imipenem, 85.1% to Amikacin, and 72.6% to  Nitrofurantoin45.
In the case of P. aeruginosa, we found it 100% sensitive to 10 antibiotics from 13 antibiotics tested. Its min-
imum sensitivity was observed to Cefalexin (7.1%) and Cefotaxime (15.4%). A similar study by Shah et al. 
reported that Imipenem, Piperacillin/Tazobactam, and Amikacin with a minimum resistance rate were the most 
effective antibiotics against P. aeruginosa in UTI  patients46. In contrast, a study by Abdollahi et al. showed that 
P. aeruginosa isolated from UTI patients were highly resistant to Ampicillin (100%), Gentamicin (66.7%), and 
Nalidixic-acid (66.7%)47. On the other hand, we found no resistance to Ampicillin and Nalidixic-acid, while 
resistance to Gentamicin was very low (13.3%).
S. agalactiae isolates in our study were highly sensitive to Linezolid, Ampicillin, Cefalexin, and Nitrofurantoin. 
In agreement with our findings, Shayanfar et al. found high susceptibility to Ampicillin (96%), Nitrofurantoin 
(95.5%), Vancomycin (95%), and Norfloxacin (96.5%). They also found the most resistance to Tetracycline 
Figure 6.  Clustering pattern of antibiotic effect for ESBL-positive bacterial strains.
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(81.6%) and Co-trimoxazole (68.9%)48, while in our study the most resistance was seen to Co-trimoxazole 
(98.7%) followed by Tetracycline (50%). Another study conducted by Tayebi et al. showed that all S. agalactiae 
urinary isolates were sensitive to Linezolid and Vancomycin, 99.6% to Ampicillin and nitrofurantoin, which is 
in line with our results. Nevertheless, they showed 12% sensitivity to Tetracycline which was lower than ours 
(50%)49.
Regarding E. faecalis isolates, we found Nitrofurantoin (98%), Linezolid (97.9%), Ampicillin (96%), and 
Vancomycin (87.2%) as the most effective antibiotics. Similar to our results, Goel et al. reported that E. faecalis 
isolated from UTI patients was highly sensitive to Linezolid (100%), Nitrofurantoin (86%), Vancomycin (77.1%), 
Gentamicin (67.3%), Ampicillin (63.9%), and Ciprofloxacin (31.2%)50. Their Gentamicin susceptibility was more 
than ours. Further, Akhter et al. demonstrated considerable sensitivity to Vancomycin (100%), Nitrofurantoin 
(85.72%), and Ciprofloxacin (23.81%), which is similar to this study’s findings. They also showed 28.58 sensitivity 
rate for Gentamicin and Co-trimoxazole, which is different with our  results51.
Concerning C. diversus isolates, they were highly sensitive to Ceftriaxone (100%), Amikacin (95.5%), and 
Imipenem (95.5%). Sami et al. found that Citrobacter species isolated from UTI patients were sensitive to Imi-
penem (100), Amikacin (85.2%), and Gentamicin (77.4%), which is consistent with our findings. In addition, 
they found sensitivity to Nitrofurantoin (66.1%), Ciprofloxacin (56.2%), Ceftriaxone (50.9%), and cefotaxime 
(43.3%) which are lower than  ours52.
Considering the results of antibiogram test for K. oxytoca isolates, the greatest sensitivity was related to Imi-
penem (100%) and Amikacin (92.3%). This agrees with Razzaque et al.’s study which found Imipenem (94.7%) 
and Amikacin (92.3%) as the most effective antibiotics for K. oxytoca urinary isolates. They also found sensitivity 
to Nitrofurantoin (84.6%) and Gentamicin (65.5%), which are different to our  results53.
Depending on the ESBL-positive or negative bacteria, this study suggested that ESBL-producing isolates had 
higher resistance to some antibiotics tested compared to non-ESBL producers. For example, ESBL-positive iso-
lates of E. coli were more resistant to antibiotics tested except Amikacin, Imipenem, Meropenem, and Nitrofuran-
toin. ESBL-producing K. pneumoniae presented a higher resistance rate to Ceftazidime, Cefotaxime, Ceftriaxone, 
Gentamycin, Cefalexin, Nalidixic-acid, and Co-trimoxazole. Also, in C. diversus isolates, ESBL production caused 
resistance to antimicrobial agents except for Amikacin and Imipenem. Regarding K. oxytoca, it led to resistance 
to Ceftazidime, Cefotaxime, Norfloxacin, Cefalexin, and Co-trimoxazole.
In line with these outcomes, a study carried out by Poovendran et al. indicated that resistance to Tetracy-
cline, Amikacin, Ampicillin, Tobramycin, and Norfloxacin was comparatively higher among uropathogenic 
E. coli ESBL-producer than non-ESBL producer. Nevertheless, both groups of isolates were 100% sensitive to 
 Imipenem54. Furthermore, Albu et al. found that ESBL-producing E. coli and K. pneumoniae isolates were more 
resistant to most of the antibiotics tested compared to non-ESBLs, except for Amikacin for E. coli and Imipenem 
for K. pneumoniae, which had lower resistance rates than non-ESBLs55. Further, another study by Abayneh et al. 
indicated that ESBL-positive bacteria had higher resistance to most of the antimicrobial agents tested, while in 
both ESBL-producing and non-ESBL-producing isolates, no resistance was observed toward Imipenem and 
resistance to Amikacin was  low56. Additionally, we used Hierarchical clustering analysis based on the antibio-
gram pattern of ESBL-negative/positive E. coli, K. pneumoniae and K. oxytoca strains for clustering antibiotics 
with similar effects. In the case of ESBL positive strains, the results showed that the effectiveness of Cephalexin, 
Cefotaxime, and Ceftazidime was similar to that of Ampicillin, an antibiotic which had poor effect, and about 
the ESBL-negative strains, Amikacin and Imipenem demonstrated the most similarity in their efficacy.
In conclusion, the current study indicated a significant rate of infection with ESBL-producing Gram-negative 
bacilli among UTI patients. The ESBL production was found predominantly among E. coli followed by Klebsiella 
spp. An intensifying level of resistance to various classes of antimicrobial agents was observed among ESBL 
producers compared with non-ESBLs.
Hierarchical cluster analysis on the antibiogram pattern showed that in ESBL-positive bacterial strains, the 
efficacy of Cephalosporins; Cephalexin, Cefotaxime, and Ceftazidime was similar to that of Ampicillin, an anti-
biotic that had very little effect. With respect to the results of this research and similar investigations worldwide, 
Carbapenems and aminoglycosides were confirmed as the best options for antibiotic therapy against the ESBL-
producing isolates. On the other hand, Penicillins and Co-trimoxazole are not recommended in the treatment 
of these bacteria; also, the administration of Cephalosporins should be limited. In conclusion, given the rise of 
antibiotic resistance and the high prevalence of ESBL production in Gram-negative bacteria, plus the importance 
of this issue in the field of treatment and public health and the costs associated with it, precise infection control 
and careful monitoring of antibiotic administration is crucial. Thus, routine screening of ESBL-producing iso-
lates before prescribing antibiotics is recommended to prevent prolonged and inappropriate use of antibiotics 
and therapeutic failures.
Received: 18 August 2020; Accepted: 14 December 2020
References
 1. Chiang, C.-Y. et al. Mitigating the impact of antibacterial drug resistance through host-directed therapies: Current progress, 
outlook, and challenges. mBio 9, e01932-1917. https ://doi.org/10.1128/mBio.01932 -17 (2018).
 2. Saipriya, J. B., Shubha, D. S., Sudhindra, K. S., Sumantha, A. & Madhuri, K. R. Clinical importance of emerging ESKAPE patho-
gens and antimicrobial susceptibility profile from a tertiary care centre. Int. J. Curr. Microbiol. Appl. Sci. 7, 2881–2891. https ://doi.
org/10.20546 /ijcma s.2018.705.336 (2018).
 3. O’Neill, J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations; Review on Antimicrobial Resistance 
(Wellcome Trust, London, 2016).
 4. Patel, M. P. et al. Synergistic effects of functionally distinct substitutions in β-lactamase variants shed light on the evolution of 
bacterial drug resistance. J. Biol. Chem. 293, 17971–17984. https ://doi.org/10.1074/jbc.RA118 .00379 2 (2018).
10
Vol:.(1234567890)
Scientific Reports |          (2021) 11:578  | https://doi.org/10.1038/s41598-020-79791-0
www.nature.com/scientificreports/
 5. Ur Rahman, S. et al. The growing genetic and functional diversity of extended spectrum beta-lactamases. Biomed. Res. Int. 2018, 
9519718. https ://doi.org/10.1155/2018/95197 18 (2018).
 6. Eiamphungporn, W., Schaduangrat, N., Malik, A. A. & Nantasenamat, C. Tackling the antibiotic resistance caused by class A 
β-lactamases through the use of β-lactamase inhibitory protein. Int. J. Mol. Sci. 19, 2222. https ://doi.org/10.3390/ijms1 90822 22 
(2018).
 7. Tewari, R. et al. Prevalence of extended spectrum β-lactamase, AmpC β-lactamase and metallo β-lactamase mediated resistance 
in Escherichia coli from diagnostic and tertiary healthcare centers in south Bangalore, India. Int. J. Res. Med. Sci. 6, 1308–1313. 
https ://doi.org/10.18203 /2320-6012.ijrms 20181 288 (2018).
 8. Ye, Q. et al. Characterization of extended-spectrum β-lactamase-producing Enterobacteriaceae from retail food in China. Front. 
Microbiol. 9, 1709. https ://doi.org/10.3389/fmicb .2018.01709 (2018).
 9. Madhi, F. et al. Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: 
A French prospective multicenter study. PLoS ONE 13, e0190910. https ://doi.org/10.1371/journ al.pone.01909 10 (2018).
 10. Rajivgandhi, G., Maruthupandy, M., Ramachandran, G., Priyanga, M. & Manoharan, N. Detection of ESBL genes from ciprofloxacin 
resistant Gram negative bacteria isolated from urinary tract infections (UTIs). Front. Lab. Med. 2, 5–13. http://creat iveco mmons 
.org/licen ses/by-ncnd/4.0/ (2018).
 11. Taghizadeh, S. et al. Epidemiology of extended spectrum Β-lactamase producing gram negative bacilli of community acquired 
urinary tract infection in Tabriz, Iran. J. Res. Med. Dent. Sci. 6, 199–204. https ://doi.org/10.24896 /jrmds .20186 231 (2018).
 12. Baziboroun, M., Bayani, M., Poormontaseri, Z., Shokri, M. & Biazar, T. Prevalence and antibiotic susceptibility pattern of extended 
spectrum beta lactamases producing Escherichia coli isolated from outpatients with urinary tract infections in Babol, Northern of 
Iran. Curr. Issues Pharm. Med. Sci. 31, 61–64. https ://doi.org/10.1515/cipms -2018-0013 (2018).
 13. Stadler, T. et al. Transmission of ESBL-producing Enterobacteriaceae and their mobile genetic elements—Identification of sources by 
whole genome sequencing: Study protocol for an observational study in Switzerland. BMJ Open 8, e021823. https ://doi.org/10.1136/
bmjop en-2018-02182 3 (2018).
 14. Shakya, P., Shrestha, D., Maharjan, E., Sharma, V. K. & Paudyal, R. ESBL production among E. coli and Klebsiella spp. causing 
urinary tract infection: A hospital based study. Open Microbiol. J. 11, 23–30. https ://doi.org/10.2174/18742 85801 71101 0023 (2017).
 15. McNulty, C. A. M. et al. CTX-M ESBL-producing Enterobacteriaceae: Estimated prevalence in adults in England in 2014. J. Anti-
microb. Chemother. 73, 1368–1388. https ://doi.org/10.1093/jac/dky00 7 (2018).
 16. Teklu, D. S. et al. Extended-spectrum beta-lactamase production and multi-drug resistance among Enterobacteriaceae isolated in 
Addis Ababa, Ethiopia. Antimicrob. Resist. Infect. Control 8, 39. https ://doi.org/10.1186/s1375 6-019-0488-4 (2019).
 17. Moustafa, A. et al. Microbial metagenome of urinary tract infection. Sci. Rep. 8, 4333. https ://doi.org/10.1038/s4159 8-018-22660 
-8 (2018).
 18. Giwa, F. J., Ige, O. T., Haruna, D. M., Yaqub, Y., Lamido, T. Z. & Usman, S. Y. Extended-spectrum beta-lactamase production and 
antimicrobial susceptibility pattern of uropathogens in a Tertiary Hospital in Northwestern Nigeria. Ann. Trop. Pathol. 9, 11–6. 
http://www.atpjo urnal .org/text.asp?2018/9/1/11/23415 5 (2018).
 19. Meije, Y. et al. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae 
producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study. Int. J. Antimicrob. Agents 54, 
189–196. https ://doi.org/10.1101/30424 6 (2019).
 20. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing. 28th edn. CLSI 
supplement M100 (CLSI, Wayne, 2018).
 21. Behzadi, P., Behzadi, E. & Pawlak-Adamska, E. A. Urinary tract infections (UTIs) or genital tract infections (GTIs)? It’s the diag-
nostics that count. GMS Hyg. Infect. Control. 14, Doc14. http://www.egms.de/en/journ als/dgkh/2019-14/dgkh0 00320 (2019).
 22. Yadav, K. & Prakash, S. Screening of ESBL producing multidrug resistant E. coli from urinary tract infection suspected cases in 
Southern Terai of Nepal. J. Infect. Dis. Diagn. 2, 116. https ://doi.org/10.4172/2576-389X.10001 16 (2017).
 23. Alqasim, A., Abu Jaffal, A. & Alyousef, A. A. Prevalence of multidrug resistance and extended-spectrum β-lactamase car-
riage of clinical uropathogenic Escherichia coli isolates in Riyadh, Saudi Arabia. Int. J. Microbiol. 2018, 3026851. https ://doi.
org/10.1155/2018/30268 51 (2018).
 24. Akhtar, N., Rahman, R., Sultana, S. & Rahman, M. R. Antimicrobial sensitivity pattern of bacterial pathogens associated with 
urinary tract infection. Delta. Med. Coll. J. 5, 57–62 (2017).
 25. Raja, N. S. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) 
producing Enterobacteriaceae. J. Infect. Public Health 12, 843–846. https ://doi.org/10.1016/j.jiph.2019.05.012 (2019).
 26. Shrestha, A., Manandhar, S., Pokharel, P., Panthi, P. & Chaudhary, D. K. Prevalence of extended spectrum beta-lactamase (ESBL) 
producing multidrug resistance gram-negative isolates causing urinary tract infection. EC Microbiol. 4, 749–755 (2016).
 27. Kengne, M., Dounia, A. T. & Nwobegahay, J. M. Bacteriological profile and antimicrobial susceptibility patterns of urine culture 
isolates from patients in Ndjamena, Chad. Pan Afr. Med. J. 28, 258. https ://doi.org/10.11604 /pamj.2017.28.258.11197 (2017).
 28. Rimal, U., Thapa, S. & Maharjan, R. Prevalence of extended spectrum beta-lactamase producing Escherichia coliand Klebsiellaspe-
cies from urinary specimens of children attending Friendship International Children’s Hospital. Nepal J. Biotechnol. 5, 32–38. https 
://doi.org/10.3126/njb.v5i1.18868 (2017).
 29. Al Yousef, S. A. et al. Clinical and laboratory profile of urinary tract infections associated with extended spectrum β-lactamase 
producing Escherichia coli and Klebsiella pneumoniae. Ann. Clin. Lab. Sci. 46, 393–400 (2016).
 30. Falodun, O. I., Morakinyo, Y. M. & Fagade, O. E. Determination of water quality and detection of extended beta-lactamase produc-
ing gram-negative bacteria in selected rivers located in Ibadan, Nigeria. Jord. J. Biol. Sci. 11, 107–112 (2018).
 31. Fatima, S. et al. Incidence of multidrug resistance and extended-spectrum beta-lactamase expression in community-acquired uri-
nary tract infection among different age groups of patients. Indian J. Pharmacol. 50, 69–74. https ://doi.org/10.4103/ijp.IJP_200_17 
(2018).
 32. Nanoty, V. V., Agrawal, G. N. & Tankhiwale, S. S. Evaluation of antibiotic resistance and β-lactamase production in clinical isolates 
from a tertiary care Hospital in Central India. J. Clin. Basic Res. 2, 1–5. https ://doi.org/10.29252 /jcbr.2.1.1 (2018).
 33. Kargar, M., Kargar, M., Jahromi, M. Z., Najafi, A. & Ghorbani-Dalini, S. Molecular detection of ESBLs production and antibiotic 
resistance patterns in Gram negative bacilli isolated from urinary tract infections. Indian J. Pathol. Microbiol. 57, 244–248. http://
www.ijpmo nline .org/text.asp?2014/57/2/244/13468 8 (2014).
 34. Yousefipour, M. et al. Bacteria producing extended spectrum β-lactamases (ESBLs) in hospitalized patients: Prevalence, antimi-
crobial resistance pattern and its main determinants. Iran. J. Pathol. 14, 61–67. https ://doi.org/10.30699 /ijp.14.1.61 (2019).
 35. Eltai, N. O. et al. Molecular characterization of extended spectrum β-lactamases enterobacteriaceae causing lower urinary tract 
infection among pediatric population. Antimicrob. Resist. Infect. Control 7, 90. https ://doi.org/10.1186/s1375 6-018-0381-6 (2018).
 36. Bharara, T. et al. Comparative analysis of extended-spectrum beta-lactamases producing uropathogens in outpatient and inpatient 
departments. Int. J. Health Allied Sci. 7, 45–50. https ://doi.org/10.4103/ijhas .IJHAS _33_17 (2018).
 37. Kalaivani, R., Charles, P., Kunigal, S. & Prashanth, K. Incidence of SHV-1 and CTX-M-15 extended spectrum of β-lactamases 
producing Gram-negative bacterial isolates from antenatal women with asymptomatic bacteriuria. J. Clin. Diagn. Res. 12, 1–4. 
https ://doi.org/10.7860/JCDR/2018/35728 .11568 (2018).
 38. Koksal, E. et al. Investigation of risk factors for community-acquired urinary tract infections caused by extended-spectrum beta-
lactamase Escherichia coli and Klebsiella species. Investig. Clin. Urol. 60, 46–53. https ://doi.org/10.4111/icu.2019.60.1.46 (2019).
11
Vol.:(0123456789)
Scientific Reports |          (2021) 11:578  | https://doi.org/10.1038/s41598-020-79791-0
www.nature.com/scientificreports/
 39. Taha, A. A., Shtawi, A., Jaradat, A. & Dawabsheh, Y. Prevalence and risk factors of extended spectrum beta-lactamase-producing 
uropathogens among UTI patients in the governmental hospitals of North West Bank: A cross-sectional study. J. Infect. Dis. Preve. 
Med. 6, 183. https ://doi.org/10.4172/2329-8731.10001 83 (2018).
 40. Senbayrak, S. et al. Antibiotic resistance trends and the ESBL prevalence of Escherichia coli and Klebsiella spp urinary isolates in 
in-and outpatients in a tertiary care hospital in Istanbul, 2004–2012. Jundishapur J. Microbiol. 10, e13098. https ://doi.org/10.5812/
jjm.13098 (2017).
 41. Ahmed, S. S., Shariq, A., Alsalloom, A. A., Babikir, I. H. & Alhomoud, B. N. Uropathogens and their antimicrobial resistance 
patterns: Relationship with urinary tract infections. Int. J. Health Sci. 13, 48–55 (2019).
 42. Mohammed, M. A., Alnour, T. M., Shakurfo, O. M. & Aburass, M. M. Prevalence and antimicrobial resistance pattern of bacterial 
strains isolated from patients with urinary tract infection in Messalata Central Hospital, Libya. Asian Pac. J. Trop. Med. 9, 771–776. 
https ://doi.org/10.1016/j.apjtm .2016.06.011 (2016).
 43. Shakibaie, M. R., Adeli, S. & Salehi, M. H. Antimicrobial susceptibility pattern and ESBL production among uropathogenic 
Escherichia coli isolated from UTI children in pediatric unit of a hospital in Kerman, Iran. Br. Microbiol. Res. J. 4, 262–273. https 
://doi.org/10.9734/BMRJ/2014/6563 (2014).
 44. Koshesh, M., Mansouri, S., Hashemizadeh, Z. & Kalantar-Neyestanaki, D. Identification of extended-spectrum β-lactamase genes 
and AmpC-β-lactamase in clinical isolates of Escherichia colirecovered from patients with urinary tract infections in Kerman, Iran. 
Arch. Pediatr. Infect. Dis. 5, e37968. https ://doi.org/10.5812/pedin fect.37968 (2017).
 45. Khan, I. U. et al. Antimicrobial susceptibility pattern of bacteria isolated from patients with urinary tract infection. J. Coll. Physi-
cians Surg. Pak. 24, 840–844. https ://doi.org/10.2014/JCPSP .84084 4 (2014).
 46. Saha, S. et al. Antimicrobial resistance in uropathogen isolates from patients with urinary tract infections. Biomed. Res. Ther. 2, 
263–269. https ://doi.org/10.7603/s4073 0-015-0011-3 (2015).
 47. Abdulahi, I. I. & Gebre-Selassie, S. Common bacterial pathogens and their antimicrobial susceptibility patterns in patients with 
symptomatic urinary tract infections at Hiwot-Fana and Jugal Hospitals, Harar City, Eastern Ethiopia. Galore Int. J. Health. Sci. 
Res. 3, 33–49 (2018).
 48. Shayanfar, N. et al. Group B streptococci urine isolates and their antimicrobial susceptibility profiles in a group of Iranian females: 
Prevalence and seasonal variations. Acta Clin. Croat. 51, 623–626 (2012).
 49. Tayebi, Z. et al. Evaluation of antimicrobial susceptibility of Streptococcus agalactiae isolates from patients with urinary tract 
infection (UTI) symptoms. Infect. Epidemiol. Med. 2, 17–19. https ://doi.org/10.18869 /modar es.iem.2.4.17 (2016).
 50. Goel, V., Kumar, D., Kumar, R., Mathur, P. & Singh, S. Community acquired enterococcal urinary tract infections and antibiotic 
resistance profile in North India. J. Lab. Physicians 8, 50–54. https ://doi.org/10.4103/0974-2727.17623 7 (2016).
 51. Akhter, J., Ahmed, S. & Anwar, S. Antimicrobial susceptibility patterns of Enterococcus species isolated from urinary tract infec-
tions. Bangladesh J. Med. Microbiol. 8, 16–20. https ://doi.org/10.3329/bjmm.v8i1.31069 (2014).
 52. Sami, H. et al. Citrobacteras a uropathogen, its prevalence and antibiotics susceptibility pattern. CHRISMED J. Health Res. 4, 23–26. 
https ://doi.org/10.4103/2348-3334.19603 7 (2017).
 53. Razzaque, S. A. et al. A cross sectional study highlighting the sensitivity patterns and incidence of extended spectrum beta lactamase 
producing Klebsiella oxytoca in patients with urinary tract infection. Int. J. Pulmonol. Infect. Dis. 1, 1–5. https ://doi.org/10.15226 
/2637-6121/1/1/00102 (2017).
 54. Poovendran, P., Vidhya, N. & Murugan, S. Antimicrobial susceptibility pattern of ESBL and non-ESBL producing uropathogenic 
Escherichia coli (UPEC) and their correlation with biofilm formation. Int. J. Microbiol. Res. 4, 56–63. https ://doi.org/10.5829/idosi 
.ijmr.2013.4.1.71235 (2013).
 55. Albu, S. et al. Bacteriuria and asymptomatic infection in chronic patients with indwelling urinary catheter: The incidence of ESBL 
bacteria. Medicine 97, e11796. https ://doi.org/10.1097/MD.00000 00000 01179 6 (2018).
 56. Abayneh, M., Tesfaw, G. & Abdissa, A. Isolation of extended-spectrum β-lactamase-(ESBL-)producing Escherichia coli and Kleb-
siella pneumoniae from patients with community-onset urinary tract infections in Jimma University Specialized Hospital, Southwest 
Ethiopia. Can. J. Infect. Dis. Med. Microbiol. 2018, 4846159. https ://doi.org/10.1155/2018/48461 59 (2018).
Acknowledgements
The authors would like to thank the technical staff of Fardis Central Laboratory particularly for their valuable 
assistance in collecting and processing of specimens. Also, we are grateful to the research staff of the Department 
of Medical Laboratory Sciences, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran, 
for contribution to improving the quality of this research.
Author contributions
M.J.G. and N.R. conceived the study and designed experiments. P.R.A., M.S. and Z.Y. conducted the experiment. 
J.Z. analysed the data. P.R.A. drafted the first manuscript. All authors reviewed the manuscript.
Competing interests 
The authors declare no competing interests.
Additional information
Correspondence and requests for materials should be addressed to N.R.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2021
